[Prevention and treatment of hepatic encephalopathy].

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.17116/jnevro2017117101144-147PMID 29171503
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• L‐ornithine L‐aspartate in bouts of overt hepatic encephalopathy

  2018cited by this paper
• Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis

  2017cited by this paper
• Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.

  2017cited by this paper
• Branched-chain amino acid supplementation in treatment of liver cirrhosis: Updated views on how to attenuate their harmful effects on cataplerosis and ammonia formation.

  2017cited by this paper
• Hepatic encephalopathy: a critical current review

  2017cited by this paper
• Concurrent assessment of calpain and caspase3 activities in brains of mice with acetaminophen-induced acute hepatic encephalopathy

  2017cited by this paper
• Concurrent assessment of calpain and caspase3 activities in brains of mice with acetaminophen-induced acute hepatic encephalopathy

  2017cited by this paper
• Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options

  2017cited by this paper
• Current state of knowledge of hepatic encephalopathy (Part V): clinical efficacy of L-ornithine-L-aspartate in the management of HE

  2016cited by this paper
• Organ Distribution of 13N Following Intravenous Injection of [13N]Ammonia into Portacaval-Shunted Rats

  2016cited by this paper
• Ammonia toxicity: from head to toe?

  2016cited by this paper
• RiMINI – the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial

  2016cited by this paper
• Hepatic Encephalopathy: Pharmacological Therapies Targeting Ammonia

  2016cited by this paper
• Should We Treat Minimal/Covert Hepatic Encephalopathy, and with What?

  2015cited by this paper
• Treatment of Overt Hepatic Encephalopathy.

  2015cited by this paper
• Novel Ammonia-Lowering Agents for Hepatic Encephalopathy.

  2015cited by this paper
• [Options in the treatment of hepatic encephalopathy].

  2015cited by this paper
• Cerebral effects of ammonia in liver disease: current hypotheses

  2014cited by this paper
• Oral l‐ornithine‐l‐aspartate in minimal hepatic encephalopathy: A randomized, double‐blind, placebo‐controlled trial

  2014cited by this paper
• Pathophysiology, diagnosis, and management of hepatic encephalopathy

  2014cited by this paper
• Effect of Rifaximin, Probiotics, and l-Ornithine l-Aspartate on Minimal Hepatic Encephalopathy: A Randomized Controlled Trial

  2014cited by this paper
• Randomised clinical trial: l‐ornithine‐l‐aspartate reduces significantly the increase of venous ammonia concentration after TIPSS

  2014cited by this paper
• Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.

  2013cited by this paper
• Hepatic encephalopathy: from pathophysiology to therapeutic management

  2011cited by this paper
• Mechanisms, diagnosis and management of hepatic encephalopathy

  2010cited by this paper
• Clinical Efficacy of L-Ornithine–L-Aspartate in the Management of Hepatic Encephalopathy

  2002cited by this paper
• Therapeutic efficacy of L‐ornithine‐L‐aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo‐controlled, double‐blind study

  1997cited by this paper

• Hepatic encephalopathy: issues relevant to clinical practice

  2021cites this paper
• Prognosis of Patients with Sepsis and Non-Hepatic Hyperammonemia: A Cohort Study

  2020cites this paper